{"id":"b62727ce9aa0","type":"article","url":"https://hartvaat.nl/2026/02/28/clopidogrel-versus-aspirine-bij-coronairlijden-kanttekeningen-bij-meta-analyse/","title":"Clopidogrel versus aspirine bij coronairlijden: kanttekeningen bij meta-analyse","title_en":"","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["anticoagulantia","aspirine","bisoprolol","clear-outcomes","statines","trombocytenaggregatieremmers"],"journal":"The Lancet","doi":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02643-1/fulltext","source_url":"https://doi.org/https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02643-1/fulltext","authors":["Agostino Colli","Giovanni Casazza","Christian Gluud"],"significance":5,"published":"2026-03-31","source_date":"2026-02-28","image":"","kennis":["https://hartvaat.nl/kennis/preventie/aspirine-primaire-preventie/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"This Lancet correspondence raises methodological concerns about a recent meta-analysis by Valgimigli et al. comparing clopidogrel versus aspirin for secondary prevention in coronary artery disease. The authors point out limitations that nuance the conclusion of clopidogrel superiority.","created":"2026-07-03T10:32:40Z","updated":"2026-07-03T13:31:36Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Deze Lancet-correspondentie plaatst kanttekeningen bij de recente meta-analyse van Valgimigli et al. over clopidogrel versus aspirine als secundaire preventie bij coronairlijden. De auteurs wijzen op methodologische beperkingen die de conclusie dat clopidogrel superieur is aan aspirine nuanceren.","abstract_original":"We read with interest the systematic review and meta-analysis on clopidogrel versus aspirin for secondary prevention of coronary artery disease by Marco Valgimigli and colleagues.1 This review included seven randomised trials with individual patient data from 28 982 patients and found a lower incidence of major adverse cardiovascular or cerebrovascular events (MACCE) with clopidogrel (929 events; 2·61 per 100 patient-years) compared with aspirin (1062 events; 2·99 per 100 patient-years).1 Most trials were open-label and industry-funded, yet all were judged as having a low risk of bias."}